Navigation Links
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Date:3/31/2009

-- New Claims Cover Phospholipid-Targeting Compounds Linked to Anti-Viral Agents --

TUSTIN, Calif., March 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported the issuance of a U.S. patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases. The new patent grants composition of matter claims that cover multiple formulations of phosphatidylethanolamine (PE)-binding agents attached to a wide variety of anti-viral agents. PE belongs to the aminophospholipid family that also includes phosphatidylserine (PS), the target for Peregrine's monoclonal antibody bavituximab that is in a clinical trial for hepatitis C virus (HCV) infection and in preclinical studies for HIV and other viral infections. This new patent follows issuance last year of broad methods patents covering use of PE-binding agents in anti-viral applications.

"Our anti-viral program has gained momentum over the past year with prestigious scientific publications and presentations, as well as the award of a major federal contract to Peregrine for the development of our anti-PS antibodies for biodefense applications," said Steven W. King, president and CEO of Peregrine. "Our growing patent estate in the closely related field of anti-PE binding agents should provide us with additional scientific and strategic options for leveraging our promising anti-viral assets."

The science underlying Peregrine's patents for anti-viral applications of PE-targeting agents was presented at a scientific conference last year by Dr. Melina Soares of the University of Texas Southwestern Medical Center(1). Dr. Soares presented data showing that similar to PS, the aminophospholipid PE is normally located on t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
6. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
7. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. ... and patient recruitment services. The core expertise of PRC Clinical is focused on ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... says the company is making good progress in evaluating the full range of ... tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and repair ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... leading campus recruitment company, has announced the official ... new website is designed for students, recent graduates, ... the biotechnology, pharmaceutical, and life sciences industries. With ... more people are considering a career in these ...
... in their use of energy and materials, according to ... 20 major manufacturing processes. , Overall, new manufacturing systems ... consumers of energy, per pound of output, than more ... uses up orders of magnitude more energy than making ...
... , March 27 VIA Pharmaceuticals, Inc. (Nasdaq: ... the development of compounds for the treatment of cardiovascular ... Marketplace Rule 4350(b)(1)(B), that the independent audit report included ... the fiscal year ended December 31, 2008 and filed ...
Cached Biology Technology:Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 2Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 3MIT: 'Alarming' use of energy in modern manufacturing methods 2MIT: 'Alarming' use of energy in modern manufacturing methods 3VIA Pharmaceuticals Complies With NASDAQ Rules 2VIA Pharmaceuticals Complies With NASDAQ Rules 3VIA Pharmaceuticals Complies With NASDAQ Rules 4
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... tends to conjure up images of tropical vacations, complete ... Rapid climate change, and increased pollution, ocean acidification ... factors heavily stress corals, and thus put both the ... and shelter, and the $1 billion dollar tourism industry ...
... cell, little bubbles called vesicles serve as container ships, ... cell membrane. Some of these vesicles, called post-Golgi vesicles, ... Scientists have long believed that other, similar vesicles handle ... an independent process. By using a finely honed type ...
... Researchers studying the nervous control of nematode mating behavior ... to mate with a hermaphrodite. Writing in the open ... Paul Sternberg from the California Institute of Technology investigated ... tail muscles to achieve an exploratory embrace. ...
Cached Biology News:Cells use import machinery to export their goods as well 2Cells use import machinery to export their goods as well 3
... General description: Aminopropylsilane ... commonly used slide chemistry ... APS Coated Slides for ... reliable glass substrate for ...
Designed for use with any of the Agencourt kits in tube format....
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,405-4) or contact customer service ... mm volume diam. 3 mL ...
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
Biology Products: